The Israeli medical device startup Butterfly Medical announced last week that its innovative medical device for non-surgical, office-based treatment of Benign Prostate Hyperplasia (BPH) has received European CE approval. This innovative device provides a simple, fast and minimally invasive, in-office procedure to BPH patients.
Photo Credit: Butterfly Medical
Last week, the Israeli medical device startup Butterfly Medical, an Alon Medtech company, announced that its innovative medical device for non-surgical, office-based treatment of Benign Prostate Hyperplasia (BPH) has received European CE approval.
BPH affects about 105 million men globally, the majority of whom are over the age of 50. According to Prostate Cancer UK, four out of every 10 men over the age of 50 have an enlarged prostate that causes them severe urinary problems.
Medication is usually the first type of therapy doctors prescribe. However, the relief can be inadequate and temporary and thus patients often end up needing invasive surgery. Butterfly Medical’s device expands the treatment options for BPH patients.
The novel device provides a simple, fast and minimally invasive, in-office procedure to BPH patients who are suffering. Butterfly Medical’s device enables doctors to treat their patients in less than 10 minutes from the comfort of their office under local anesthesia. The device provides instant relief, enabling the patients to go back to their normal activities immediately.
“We are proud to bring a simple, non-surgical treatment option to the millions of men worldwide afflicted by BPH. With our Butterfly Medical device, they are able to receive treatment quickly and easily in their physician’s office,” said Idan Geva, CEO Butterfly Medical. “With market acceptance for our medical approach already demonstrated, our closest competitor was sold for over $1 billion, our European market approval puts us right on the map.”
Chairman of Butterfly Medical and Active Chairman of Alon Medtech, Dr. Shimon Eckhouse said: “Butterfly is a great example of our approach at Alon Medtech of building successful companies with our entrepreneurs to bring innovative products to large, high growth markets. The CE approval of the Butterfly device is a very important milestone in the life of the company enabling it to access the European market in the very near future.”